Moderna shares slump 21% on lowered full-year guidance
Q2 sales and earnings beat estimatesShares plunge on full-year downgradeRSV vaccine doses ship ahead of winterInvestors can be a tough bunch to please, just beating expectations is often not enough.Biotechnology firm Moderna (MRNA) is a case in point, with its shares slumping 21% overnight despite second quarter earnings coming in ahead of Wall Street estimates as the company slashed its full year